Abstract
Glioblastoma multiforme (GBM) the most common primary brain malignancy in adults, has an approximately 25% 2-year overall survival despite improvements in both first and second-line therapies [1]. However, options still remain limited in those patients progressing after failure of temozolomide. IDH mutation and MGMT methylation status do predict whether patients will respond favorable to alkylator based therapies and clinical trials are ongoing to develop therapies specific to these GBM subtypes. In many cases, chemotherapy resistance is thought to be related to the inability of agents to cross the blood brain barrier into the tumor, limiting efficacy of otherwise effective agents.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Nuclear Medicine & Radiation Therapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
